These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3949930)

  • 21. Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction.
    Bozkurt A; Basci NE; Isimer A; Kayaalp SO
    J Pharm Biomed Anal; 1993 Aug; 11(8):745-9. PubMed ID: 8257740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
    Allen JG; East PB; Francis RJ; Haigh JL
    Drug Metab Dispos; 1975; 3(5):332-7. PubMed ID: 241613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.
    Xu XM; Jiang WD
    Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):385-8. PubMed ID: 2130590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-performance liquid chromatographic quantitation of 4-hydroxydebrisoquine in microsomal incubates by use of silica columns, aqueous mobile phase and automated column switching.
    Mellström B
    J Chromatogr; 1988 Feb; 424(2):435-9. PubMed ID: 2836450
    [No Abstract]   [Full Text] [Related]  

  • 25. [Hydroxylation of debrisoquin in Parkinson's disease].
    Meillard MN; Bentué-Ferrer D; Brunet-Bourgin F; Morel G; Allain H
    Presse Med; 1990 May; 19(20):947-9. PubMed ID: 2141131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
    Pereira VA; Auler JO; Carmona MJ; Mateus FH; Lanchote VL; Breimer DD; Santos SR
    Braz J Med Biol Res; 2000 May; 33(5):509-14. PubMed ID: 10775881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
    Philip PA; James CA; Rogers HJ
    Br J Clin Pharmacol; 1987 Dec; 24(6):827-9. PubMed ID: 3440103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidation phenotyping with debrisoquine in Germany (East).
    Zschiesche M; Hanke W; Siegmund W; Franke G; Wilke A
    Pharmazie; 1990 Dec; 45(12):920-1. PubMed ID: 2100800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography.
    Cifuentes A; Valencia J; Sanz E; Sánchez MJ; Rodríguez-Delgado MA
    J Chromatogr A; 1997 Aug; 778(1-2):389-96. PubMed ID: 9299748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis.
    Lanz M; Theurillat R; Thormann W
    Electrophoresis; 1997 Sep; 18(10):1875-81. PubMed ID: 9372283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
    Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
    Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
    Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J; LLerena A; Cobaleda J
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.